Can metoprolol and bisoprolol be given together?

No - Metoprolol and Bisoprolol Should Not Be Given Together

Do not combine metoprolol and bisoprolol, as using two beta-blockers from the same class together is explicitly contraindicated and provides no additional benefit while increasing the risk of adverse effects.

Clear Guideline Prohibition

The 2017 ACC/AHA Hypertension Guidelines explicitly state that "drug combinations that have similar mechanisms of action or clinical effects should be avoided. For example, 2 drugs from the same class should not be administered together (e.g., 2 different beta blockers)" 1, 2, 3. This is a fundamental principle of antihypertensive therapy that applies across all cardiovascular conditions.

The FDA drug labels reinforce this prohibition. The bisoprolol prescribing information specifically states: "Bisoprolol fumarate should not be combined with other beta-blocking agents" 4. This is a direct contraindication, not merely a precaution.

Why This Combination Is Harmful

Additive Adverse Effects Without Added Benefit

Both metoprolol and bisoprolol are cardioselective beta-1 blockers with overlapping mechanisms of action. Combining them creates:

• Excessive bradycardia: Both drugs slow heart rate through the same mechanism. The FDA warns that metoprolol can cause "bradycardia, including sinus pause, heart block, and cardiac arrest" 5. Adding bisoprolol compounds this risk exponentially.

• Severe hypotension: Both reduce cardiac output and blood pressure. Combining them provides no additional blood pressure reduction beyond maximizing a single agent, but dramatically increases hypotension risk.

• Heart failure exacerbation: While beta-blockers are beneficial in heart failure when properly dosed, excessive beta-blockade from two agents can precipitate acute decompensation. The metoprolol label warns that "beta-blockers can cause depression of myocardial contractility and may precipitate heart failure and cardiogenic shock" 5.

• AV conduction abnormalities: The bisoprolol label notes that "both digitalis glycosides and beta-blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia" 4. Two beta-blockers create the same compounding risk.

No Therapeutic Rationale

There is no clinical scenario where combining two beta-blockers is superior to optimizing the dose of a single agent:

• If heart rate or blood pressure control is inadequate, the solution is to uptitrate the current beta-blocker to target dose or add a medication from a different class (e.g., ACE inhibitor, calcium channel blocker, diuretic).

• The 2022 AHA/ACC Heart Failure Guidelines list specific target doses for beta-blockers in HFrEF: bisoprolol 10 mg daily, metoprolol succinate 200 mg daily, or carvedilol 25-50 mg twice daily 6. The approach is to reach these evidence-based doses with a single agent, not to combine multiple beta-blockers.

What to Do Instead

If a Patient Is on Two Beta-Blockers

This represents a prescribing error that requires immediate correction:

1. Discontinue one beta-blocker immediately - Choose to continue the agent that:

   • Has better evidence for the patient's specific condition (e.g., metoprolol succinate, bisoprolol, or carvedilol for HFrEF 6, 7)
   • The patient has tolerated longer
   • Is dosed once daily for better compliance

2. Optimize the remaining beta-blocker to target dose before considering additional agents

3. Add medications from different classes if additional rate/rhythm/blood pressure control is needed

For Inadequate Control on One Beta-Blocker

The algorithmic approach is:

1. First: Ensure the current beta-blocker is at target dose (e.g., metoprolol succinate 200 mg daily, bisoprolol 10 mg daily)

2. Second: If contraindications or intolerance prevent uptitration, consider switching to a different beta-blocker (not adding a second one)

3. Third: Add agents from complementary classes:

   • ACE inhibitors/ARBs/ARNIs for blood pressure and neurohormonal blockade
   • Calcium channel blockers (dihydropyridines only with beta-blockers; avoid diltiazem/verapamil due to additive AV nodal blockade 1)
   • Diuretics for volume management
   • For atrial fibrillation rate control: digoxin or amiodarone if beta-blocker alone insufficient 8

Common Clinical Pitfall

The most frequent error leading to dual beta-blocker therapy occurs during transitions of care when:

• A patient on metoprolol is started on bisoprolol by a different provider
• Hospital discharge medications include a beta-blocker different from the outpatient regimen
• Medication reconciliation fails to identify the duplication

Always perform thorough medication reconciliation and explicitly discontinue one agent when this error is discovered.